Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...
First-in-human trial of AB-1002 designed to evaluate safety and preliminary efficacy in participants with New York Heart Association (NYHA) Class III heart failure Trial enrolled 11 participants in ...
Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...
BioCardia announces data verification completion for Phase 3 CardiAMP HF study on heart failure treatment, with results due March 30, 2025. BioCardia, Inc. has completed source data verification and ...
Alector, Inc. is a pre-revenue biotech reset after Latozinemab’s Phase 3 failure, now trading at a deep discount. Nivisnebart, targeting Alzheimer’s, is ALEC’s next major catalyst; interim Phase 2 ...
Topline data with 12-month follow-up will be reported in due course. "The completion of enrollment in the Phase 1/2a trial marks a crucial milestone for this cardiac gene therapy trial in patients ...
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias NYHA heart failure ...
GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results